Lungpacer News & Media
Stay up to date with the latest breakthroughs,
research, and company milestones
Sort by:
Lungpacer Announces Health Economic Analysis Demonstrating Clinical and Cost Benefits of AeroPace in Mechanically Ventilated Patients
July 28, 2026
Press Release
Lungpacer Announces New Category III CPT® Codes for AeroPace® Diaphragm Neurostimulation Therapy
July 21, 2026
Press Release
Lungpacer Medical Appoints Steven Pfanstiel as Chief Financial Officer
June 1, 2026
Press Release
Lungpacer Achieves Commercial Milestone as Leading U.S. Hospital Performs First AeroPace® Procedures to Help Patients Liberate from Mechanical Ventilation
December 8, 2025
Press Release
Lungpacer Medical Announces First Enrollments in STARI Trial of Next-Generation Neurostimulation Therapy
November 4, 2025
Press Release
Lungpacer Announces CMS NTAP Approval for AeroPace® System in FY2026 IPPS Final Rule
August 14, 2025
Press Release
American Journal of Respiratory and Critical Care Medicine Publishes Landmark Data on AeroPace® System’s Breakthrough Results in Ventilator Weaning
June 12, 2025
Press Release
Kevin Kearney Joins Lungpacer Medical as Chief Commercial Officer
March 24, 2025
Press Release
Lungpacer Medical Announces Investigational Device Exemption (IDE) for STARI, Phase 2 Feasibility Clinical Trial
March 10, 2025
Press Release
